过氧化物酶体增殖物激活受体在COPD患者中的作用  

Role of PPARs in Chronic Obstructive Pulmonary Disease

作　　者：唐银平 何燕[2] TANG Yinping;HE Yan(Chengdu University of TCM,Chengdu 610075,China;Department of Respiratory Medicine,Affiliated Hospital of Chengdu University of TCM,Chengdu 610072,China)

机构地区：[1]成都中医药大学,成都610075 [2]成都中医药大学附属医院呼吸科,成都610072

出　　处：《医学综述》2019年第21期4245-4250,共6页Medical Recapitulate

摘　　要：慢性阻塞性肺疾病(COPD)是一种气道炎症性疾病,其特征是进行性气流受限,巨噬细胞和中性粒细胞浸润增加,炎症介质分泌过多,氧化和抗氧化失调。COPD作为呼吸系统常见病,仍是现代医学的一项重大挑战,目前的各种治疗方法均未能满足临床需求,故需要寻求新兴的治疗靶点。过氧化物酶体增殖物激活受体激动剂除用于代谢性疾病的治疗外,还具有强大的抗炎、免疫调节作用,并可改善COPD患者骨骼肌功能障碍、逆转糖皮质激素敏感性的降低、抗细菌感染等,可能成为COPD的新兴治疗靶点。Chronic obstructive pulmonary disease( COPD) is an airway inflammatory disease characterized by progressive airflow limitation,increased macrophage and neutrophil infiltration,and hypersecretion of inflammatory mediators,as well as oxidant and antioxidant dysregulation. COPD is a common disease in the respiratory system,which remains a major challenge for medicine,and current therapies fail to meet the clinical needs,so there is a growing need for the development of therapeutic targets. Peroxisome proliferator-activated receptors agonists have powerful anti-inflammatory and immunomodulatory effects in addition to the treatment of metabolic diseases. It can improve skeletal muscle dysfunction in COPD patients,reverse reduced corticosteroid sensitivity,and play an anti-bacterial infection role,which may become an emerging therapeutic target for COPD.

关 键 词：过氧化物酶体增殖物激活受体 慢性阻塞性肺疾病 肺气肿 骨骼肌功能障碍 糖皮质激素抵抗 

分 类 号：R563.9[医药卫生—呼吸系统]